EP1351691A4 - 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee - Google Patents

2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee

Info

Publication number
EP1351691A4
EP1351691A4 EP01990048A EP01990048A EP1351691A4 EP 1351691 A4 EP1351691 A4 EP 1351691A4 EP 01990048 A EP01990048 A EP 01990048A EP 01990048 A EP01990048 A EP 01990048A EP 1351691 A4 EP1351691 A4 EP 1351691A4
Authority
EP
European Patent Office
Prior art keywords
arylaminopyrimidines
caspases
inductors
activators
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01990048A
Other languages
German (de)
English (en)
Other versions
EP1351691A1 (fr
Inventor
Sui Xiong Cai
John A Drewe
Bao Nguyen
P Sanjeeva Reddy
Azra Pervin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Publication of EP1351691A1 publication Critical patent/EP1351691A1/fr
Publication of EP1351691A4 publication Critical patent/EP1351691A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01990048A 2000-12-12 2001-12-12 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee Withdrawn EP1351691A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25458100P 2000-12-12 2000-12-12
US254581P 2000-12-12
PCT/US2001/047498 WO2002047690A1 (fr) 2000-12-12 2001-12-12 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee

Publications (2)

Publication Number Publication Date
EP1351691A1 EP1351691A1 (fr) 2003-10-15
EP1351691A4 true EP1351691A4 (fr) 2005-06-22

Family

ID=22964830

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01990048A Withdrawn EP1351691A4 (fr) 2000-12-12 2001-12-12 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee

Country Status (3)

Country Link
EP (1) EP1351691A4 (fr)
AU (1) AU2002228922A1 (fr)
WO (1) WO2002047690A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022605A1 (fr) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP1575506A4 (fr) * 2002-07-25 2008-04-23 Scios Inc Methodes pour ameliorer la fonction respiratoire au moyen d'inhibiteurs du tgf-beta
CN1319968C (zh) 2002-08-02 2007-06-06 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
CA2439440A1 (fr) 2002-09-05 2004-03-05 Emory University Traitement de tumeurs associees a la sclerose tubereuse
BR0314196A (pt) * 2002-09-10 2005-07-26 Scios Inc Inibidores de tgf-beta
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005012294A1 (fr) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. Composes 2,4-pyrimidinediamine a utiliser dans le traitement ou la prevention de maladies auto-immunes
US6818631B1 (en) 2003-08-15 2004-11-16 Nippon Soda Co. Ltd. Fungicidal pyrimidine derivatives
EP1678146A1 (fr) * 2003-10-23 2006-07-12 Pharmacia Corporation Composes de pyrimidine utiles pour le traitement des inflammations
US8455489B2 (en) 2003-11-10 2013-06-04 Exelixis, Inc. Substituted pyrimidine compositions and methods of use
CA2545422C (fr) 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Inhibiteurs de la tubuline
CA2551944A1 (fr) * 2003-12-15 2005-06-30 Almirall Prodesfarma Ag 2, 6-bisheteroaryl-4-aminopyrimidines utilisees en tant qu'antagonistes des recepteurs de l'adenosine
CA2561895A1 (fr) * 2004-04-13 2005-10-27 Icagen, Inc. Pyrimidines polycycliques utilises en tant que modulateurs du canal ionique du potassium
JP4602686B2 (ja) * 2004-04-15 2010-12-22 広栄化学工業株式会社 ２，６−ジハロゲノ−４−アリールピリジン類の製造法
WO2006007532A2 (fr) * 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. Composes heteroaryles substitues en 2
WO2006027348A1 (fr) * 2004-09-06 2006-03-16 Basilea Pharmaceutica Ag Phenylaminopyridines
CA2581454A1 (fr) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Nouveaux composes de pyrimidine, leur procede de preparation, et compositions les contenant
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CN101146789A (zh) * 2005-01-25 2008-03-19 阿斯利康(瑞典)有限公司 化合物
DE602006020864D1 (de) * 2005-04-11 2011-05-05 Almirall Sa 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
MX2008005814A (es) 2005-11-03 2008-10-15 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
EP1878733A1 (fr) * 2006-07-14 2008-01-16 Novartis AG Dérivés de pyrimidine comme inhibiteurs de ALK-5
US20110144140A1 (en) * 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
EA019869B1 (ru) * 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
CA2840883C (fr) 2011-07-07 2019-07-16 Merck Patent Gmbh Azaheterocycles substitues
JP2014237590A (ja) * 2011-09-30 2014-12-18 アステラス製薬株式会社 ２−（ピリジン−２−イル）ピリミジン−４−アミン化合物又はその塩
ES2620316T3 (es) * 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
WO2014015936A1 (fr) * 2012-07-23 2014-01-30 Merck Patent Gmbh Ligands et leur préparation
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
NZ746607A (en) * 2012-11-21 2019-11-29 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
CN103896856B (zh) * 2012-12-25 2016-06-08 叶龙 一种多取代单环嘧啶类jnk激酶抑制剂及其制备方法和用途
CN108976172B (zh) * 2017-05-31 2021-12-07 华东师范大学 一类4-嘧啶二胺类小分子有机化合物及其衍生物及其应用
CN108715589B (zh) * 2018-06-19 2021-04-20 华侨大学 一种用作caspase-3激活剂的香豆素类衍生物及其应用
EP3836932A2 (fr) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Méthode de traitement du cancer du pancréas
JP7631193B2 (ja) 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2020176610A1 (fr) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. Procédé de traitement d'un myélome multiple
BR112021019170A2 (pt) * 2019-03-27 2022-03-03 Ptc Therapeutics Inc Combinações úteis em um método para tratar sarcoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041030A (en) * 1973-09-20 1977-08-09 Delalande S.A. Arylamino pyrimidinic derivatives
EP0629622A1 (fr) * 1992-02-28 1994-12-21 Zenyaku Kogyo Kabushikikaisha DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L' STROGENE LE CONTENANT COMME INGREDIENT ACTIF
EP0640599A1 (fr) * 1993-08-26 1995-03-01 Ono Pharmaceutical Co., Ltd. Dérivés de la 4-aminopyrimidine
WO1997009315A1 (fr) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
US6103737A (en) * 1997-07-03 2000-08-15 Dupont Pharmaceuticals Company Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006473A2 (fr) * 1993-09-01 1995-03-09 Nippon Kayaku Kabushiki Kaisha Utilisation medicale d'un compose d'acide polysulfonique
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041030A (en) * 1973-09-20 1977-08-09 Delalande S.A. Arylamino pyrimidinic derivatives
EP0629622A1 (fr) * 1992-02-28 1994-12-21 Zenyaku Kogyo Kabushikikaisha DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L' STROGENE LE CONTENANT COMME INGREDIENT ACTIF
EP0640599A1 (fr) * 1993-08-26 1995-03-01 Ono Pharmaceutical Co., Ltd. Dérivés de la 4-aminopyrimidine
WO1997009315A1 (fr) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
US6103737A (en) * 1997-07-03 2000-08-15 Dupont Pharmaceuticals Company Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 134, 10 May 2001, Columbus, Ohio, US; abstract no. 295842 *
See also references of WO0247690A1 *

Also Published As

Publication number Publication date
AU2002228922A1 (en) 2002-06-24
WO2002047690A1 (fr) 2002-06-20
EP1351691A1 (fr) 2003-10-15

Similar Documents

Publication Publication Date Title
EP1351691A4 (fr) 2-aryl-4-arylaminopyrimidines substituees et analogues en tant qu'activateurs de caspases et qu'inducteurs d'apoptose, et utilisation associee
DE60020994D1 (de) Neue verwendung sowie neue n-azabicycloamid-verbindungen
ATE280163T1 (de) Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
DE50213336D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE60309874D1 (de) Malonsäuerenitril-verbindungen und ihre verwendung als pestizide
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
ATE297386T1 (de) Biphenylderivate und ihre verwendung als aktivatoren des ppar-gamma-rezeptors
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60230131D1 (de) Malonitril-verbindungen und ihre verwendung als pestizide
DE69817611D1 (de) 2-aryl-8-oxodihydropurin-derivate, ihre herstellung, ihre verwendung als medikamentenkomponente und deren intermediate
ATE340160T1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
ATE367381T1 (de) Neue spirotricyclische derivate und deren verwendung als phosphodiesterase-7-inhibitoren
DE60234376D1 (de) 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
ATE394102T1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
ATE297921T1 (de) Tetrazolylphenyl-acetamide als glukokinaseaktivatoren
DE60332337D1 (de) Neue Vip3-Toxine und ihre Verwendung
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE50212455D1 (de) Verwendung von Dimerdiolen
ATE420642T1 (de) Neue formulierungen und ihre verwendung
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE60138140D1 (de) Acyl- und sulfonylderivative 6,9-disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
DE60103394D1 (de) 4-(2-phenylthiazol-5-yl)1,4-diazabicyclo[3.2.2]nonanederivate, ihre herstellung und therapeutische verwendung
DE60313895D1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

17Q First examination report despatched

Effective date: 20051117

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070712BHEP

Ipc: C07D 401/14 20060101ALI20070712BHEP

Ipc: C07D 401/04 20060101ALI20070712BHEP

Ipc: C07D 239/48 20060101ALI20070712BHEP

Ipc: C07D 239/42 20060101ALI20070712BHEP

Ipc: A61K 31/506 20060101ALI20070712BHEP

Ipc: A61K 31/505 20060101ALI20070712BHEP

Ipc: A61K 31/53 20060101ALI20070712BHEP

Ipc: A61K 31/50 20060101AFI20070712BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080111